Zandelisib + Tazemetostat in R/R Follicular Lymphoma

Status Withdrawn

Clinical Trial Summary

This research study is being done to estimate the safety and efficacy of zandelisib and tazemetostat in people with relapsed or refractory follicular lymphoma (FL) This research study involves Zandelisib in combination with Tazemetostat. MEI Pharma, Inc, a biotechnology company, is supporting this research study by providing funding for the research study, including the study drug zandelisib.

Clinical Trial Description

This is a phase 1 study of Zandelisib and Tazemetostat with a phase 2 expansion two-arm component in patients with relapsed or refractory follicular lymphoma (FL) grade 1-3A. - This research study involves Zandelisib in combination with Tazemetostat. This is the first time the drug combination of Zandelisib and Tazemetostat will be given to humans. - The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits - Participants will receive study treatment as long as treatment is tolerated and the disease does not worsen. - The maximum length of time on the study drug combination is 14 months. Participants will followed for up to 2 years. - It is expected that about 34 people will take part in this research study. The U.S. Food and Drug Administration (FDA) has not approved zandelisib as a treatment for any disease. The U.S. FDA has approved tazemetostat as a treatment for relapsed or refractory follicular lymphoma as a single therapy. This is the first time this drug combination will be given to humans. This is a Phase I/II clinical trial. Participants will be asked to participate in either the Phase I part or Phase II part of this clinical trial. - A Phase I clinical trial tests the safety of an investigational drug and also tries to define the appropriate dose of the investigational drug to use for further studies. - A Phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific disease. "Investigational" means that the drug is being studied. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05604417
Study type	Interventional
Source	Massachusetts General Hospital
Contact
Status	Withdrawn
Phase	Phase 1/Phase 2
Start date	January 2023
Completion date	December 1, 2026

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05848765` - Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy	Phase 2
Withdrawn	`NCT04635683` - Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma	Phase 1
Active, not recruiting	`NCT01955499` - Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma	Phase 1
Not yet recruiting	`NCT06068881` - A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic Mutation	Phase 2
Active, not recruiting	`NCT03583424` - Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma	Phase 1/Phase 2
Recruiting	`NCT04007029` - Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia	Phase 1
Withdrawn	`NCT03579927` - CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma	Phase 1/Phase 2
Active, not recruiting	`NCT04578600` - CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma	Phase 1
Recruiting	`NCT04447716` - An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment	Phase 1
Recruiting	`NCT05025800` - ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma	Phase 1/Phase 2
Completed	`NCT03019640` - Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma	Phase 2
Completed	`NCT02927964` - TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma	Phase 1/Phase 2
Terminated	`NCT04699461` - Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma	Phase 2
Completed	`NCT02869633` - Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant	Phase 2
Active, not recruiting	`NCT02568553` - Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma	Phase 1
Completed	`NCT01995669` - Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma	Phase 1/Phase 2
Withdrawn	`NCT05152459` - Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or Refractory Follicular Lymphoma	Phase 1/Phase 2
Active, not recruiting	`NCT03401853` - Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma	Phase 2
Active, not recruiting	`NCT03479268` - Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma	Phase 1
Recruiting	`NCT06191887` - B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies	Phase 1